A stylized letter V logo with gold, purple, and orange gradient colors on a white background.

Bringing treatments to life

Accelerating value inflection with tailored clinical solutions

Map markers with flags of the United States, European Union, and China.

Clinical Redefined

​​

80% of life-saving innovations come from emerging biotechs, yet getting them to patients is where the system breaks down. Reaching human PoC remains painfully slow, capital-intensive, and high-risk. Investors increasingly want more human patient data before committing further support. But the regulatory and competitive landscape now demands that companies move even faster, show more evidence, and stay more flexible.

​

More requirements. Fewer funds. Less time.

This is where Vivara Clinical comes in: to bridge the growing gap between concept and clinical proof with a faster, more budget sensible clinical strategy, so we can continue to see the best innovations help the most patients.

​​​

Tony Xu, PhD

Managing Director, Vivara

A professional portrait of an Asian man with short black hair, glasses, wearing a navy suit, white shirt, and smiling against a gray background.
World map showing locations of the company's headquarters in Germany and Europe, with additional markers indicating trusted partners and China operations.
Infographic showing how Vivara enables global companies to leverage China advantages, featuring a map of China and the world, and sections labeled CMC, Clinical, Logistics, and Partner CMC with descriptions about their services and strategic pathways.
Infographic showing the decline of value leakage with traditional research and development, highlighting issues such as trial design uncertainty, vicious funding cycles, and changing landscape.
A presentation slide titled 'China IIT offers an attractive solution' describing financial and investment strategies, including fractional traditional trial costs, de-risking investments, and faster initiation and turnaround, with relevant icons and graphics.
Title: China IIT is already a proven path. A pie chart showing approximately 85% involvement of corporate entities and 15% of advanced therapies, including gene therapy, radioligand, stem cells, autologous, allogeneic CAR-Ts. Two notable success case descriptions: EcoBiotec, a China co-development partner who helped convince AZ for a $1 billion acquisition, and Reprogenix, which conducted an IIT prior to P1 using data to raise $500 million. Additionally, a mention of leveraging IIT to accelerate development and forge partnerships, with a chart supporting feasibility of different modalities and trial setups.
A detailed infographic outlining Vivara's unique End-to-End IITs process, including model for success, phases such as Match, Approval, Recruit, Research, and Reporting, with corresponding icons and descriptions.
A presentation slide titled 'Why US: Our extensive experience differentiates us from other options' listing achievements such as over 200 successful trials, 40+ grade 3A hospitals, 25+ Cell & Gene IITs, and 5+ Cities with extensive KOL relationships, with a map of China showing locations of network hospitals and a row of logos of various Chinese hospitals and institutions at the bottom.
A modern conference room with a large wooden table, six chairs, and large windows offering a cityscape view of historic buildings and churches.

Interested in starting a project? Contact us for more information.

Vivara Life Sciences

Learn more